Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis

What is it about?

Catheter‐related bloodstream infections (CRBSIs) are one of the most prevalent, fatal, and costly complications of hemodialysis with a central venous catheter (CVC). The LOCK IT-100 trial compared the efficacy and safety of a taurolidine/heparin catheter lock solution that combines taurolidine 13.5 mg/mL and heparin (1000 units/mL) versus heparin in preventing CRBSIs in participants receiving hemodialysis via CVC. Analysis of results in 795 study participants showed a hazard ratio of 0.29, corresponding to a 71% rhighly significant eduction in risk of CRBSI with taurolidine/heparin as compared to heparin. There were no significant differences between the two groups in time to catheter removal for any reason or loss of catheter patency. The safety of taurolidine/heparin was comparable to that of heparin, and most treatment-emergent adverse events were mild or moderate.

Featured Image